COMPUGROUP MEDICAL SOCIETAS EUROPAEA |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.35 EUR | +1.31% |
|
-7.31% | -12.91% |
| Apr. 26 | COMPUGROUP MEDICAL : Buy rating from Baader Bank | ZD |
| Apr. 25 | COMPUGROUP MEDICAL : Jefferies gives a Neutral rating | ZD |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,065 | 4,224 | 3,746 | 1,879 | 1,980 | 1,489 | - | - |
| Enterprise Value (EV) 1 | 3,505 | 4,704 | 4,374 | 2,571 | 2,682 | 2,130 | 2,044 | 1,965 |
| P/E ratio | 42.8 x | 56.1 x | 54.7 x | 25.7 x | 43.1 x | 16 x | 12.8 x | 12.5 x |
| Yield | 0.78% | 0.64% | 0.7% | 1.39% | - | 2.32% | 2.58% | 2.84% |
| Capitalization / Revenue | 4.11 x | 5.04 x | 3.65 x | 1.66 x | 1.67 x | 1.2 x | 1.15 x | 1.1 x |
| EV / Revenue | 4.7 x | 5.62 x | 4.27 x | 2.28 x | 2.26 x | 1.72 x | 1.58 x | 1.45 x |
| EV / EBITDA | 19.7 x | 22.5 x | 20.5 x | 11.9 x | 11.7 x | 7.79 x | 6.71 x | 6.25 x |
| EV / FCF | 36.6 x | 49.6 x | 43.3 x | 37.3 x | 23.7 x | 23.6 x | 15.1 x | 19.4 x |
| FCF Yield | 2.73% | 2.02% | 2.31% | 2.68% | 4.21% | 4.24% | 6.6% | 5.17% |
| Price to Book | 11.9 x | 6.62 x | 6.08 x | 2.79 x | 2.96 x | 2.08 x | 1.92 x | 1.75 x |
| Nbr of stocks (in thousands) | 48,071 | 53,735 | 52,647 | 52,235 | 52,235 | 52,235 | - | - |
| Reference price 2 | 63.75 | 78.60 | 71.15 | 35.98 | 37.90 | 28.50 | 28.50 | 28.50 |
| Announcement Date | 2/5/20 | 2/4/21 | 3/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 746 | 837.3 | 1,025 | 1,130 | 1,188 | 1,241 | 1,298 | 1,355 |
| EBITDA 1 | 178 | 209 | 213.4 | 216.4 | 229.8 | 273.2 | 304.5 | 314.5 |
| EBIT 1 | 115.6 | 133.6 | 102.7 | 104 | 114 | 158.7 | 188.9 | 201.2 |
| Operating Margin | 15.49% | 15.95% | 10.02% | 9.21% | 9.6% | 12.79% | 14.55% | 14.85% |
| Earnings before Tax (EBT) 1 | 108.8 | 110.7 | 97.9 | 106.8 | 72.67 | 141.2 | 172.2 | 171.9 |
| Net income 1 | 73.68 | 72.96 | 68.9 | 73.41 | 45.92 | 93.79 | 116.6 | 119.8 |
| Net margin | 9.88% | 8.71% | 6.72% | 6.5% | 3.87% | 7.56% | 8.98% | 8.84% |
| EPS 2 | 1.490 | 1.400 | 1.300 | 1.400 | 0.8800 | 1.783 | 2.219 | 2.278 |
| Free Cash Flow 1 | 95.81 | 94.86 | 101.1 | 68.97 | 113 | 90.32 | 135 | 101.5 |
| FCF margin | 12.84% | 11.33% | 9.86% | 6.1% | 9.51% | 7.28% | 10.4% | 7.49% |
| FCF Conversion (EBITDA) | 53.83% | 45.39% | 47.38% | 31.88% | 49.18% | 33.06% | 44.32% | 32.27% |
| FCF Conversion (Net income) | 130.03% | 130.02% | 146.75% | 93.95% | 246.1% | 96.31% | 115.75% | 84.76% |
| Dividend per Share 2 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | - | 0.6611 | 0.7356 | 0.8100 |
| Announcement Date | 2/5/20 | 2/4/21 | 3/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 276.3 | 279.2 | 251.6 | 265 | 285.4 | 327.7 | 290.8 | 304.2 | 595 | 285.7 | 306.9 |
| EBITDA 1 | 69.5 | 48.8 | 46.6 | 43.95 | 59.39 | 66.43 | 59.95 | 73.14 | 133.1 | 62.1 | 35.09 |
| EBIT 1 | 42 | 16.9 | 19.4 | 17.81 | 31.1 | 35.75 | 32.38 | 51.52 | - | 31.6 | -1.543 |
| Operating Margin | 15.2% | 6.05% | 7.71% | 6.72% | 10.9% | 10.91% | 11.13% | 16.94% | - | 11.06% | -0.5% |
| Earnings before Tax (EBT) | - | - | - | 18.19 | 43.36 | - | 20.88 | - | - | - | - |
| Net income 1 | 28.4 | 12.4 | 18.2 | 12.07 | 29.34 | 13.8 | 14.38 | 31.49 | - | 16 | -15.9 |
| Net margin | 10.28% | 4.44% | 7.23% | 4.55% | 10.28% | 4.21% | 4.94% | 10.35% | - | 5.6% | -5.18% |
| EPS | 0.5100 | 0.2800 | - | 0.2300 | 0.5600 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/10/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/9/23 | 5/10/23 | 8/10/23 | 8/10/23 | 11/9/23 | 2/7/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 440 | 480 | 628 | 691 | 703 | 641 | 556 | 476 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.472 x | 2.297 x | 2.944 x | 3.195 x | 3.058 x | 2.346 x | 1.825 x | 1.513 x |
| Free Cash Flow 1 | 95.8 | 94.9 | 101 | 69 | 113 | 90.3 | 135 | 102 |
| ROE (net income / shareholders' equity) | 28.3% | 21.9% | 16.5% | 14.7% | 16.1% | 15.4% | 16.4% | 13.5% |
| ROA (Net income/ Total Assets) | 7.69% | 7.5% | 6.15% | 5.04% | 5.6% | 5.55% | 6.14% | 6.61% |
| Assets 1 | 958.2 | 972.8 | 1,120 | 1,457 | 820.3 | 1,691 | 1,898 | 1,812 |
| Book Value Per Share 2 | 5.350 | 11.90 | 11.70 | 12.90 | 12.80 | 13.70 | 14.80 | 16.30 |
| Cash Flow per Share 2 | 2.240 | 2.900 | 3.120 | 2.770 | 3.440 | 2.820 | 3.400 | 3.700 |
| Capex 1 | 43.7 | 55.1 | 64.2 | 76.1 | 66.5 | 64.9 | 72.6 | 66.9 |
| Capex / Sales | 5.86% | 6.58% | 6.26% | 6.73% | 5.6% | 5.23% | 5.59% | 4.94% |
| Announcement Date | 2/5/20 | 2/4/21 | 3/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
28.5
EUR
Average target price
46.05
EUR
Spread / Average Target
+61.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.17% | 322B | |
| +24.75% | 216B | |
| +2.41% | 149B | |
| +10.65% | 56.27B | |
| +8.71% | 32.13B | |
| -4.57% | 27.45B | |
| +103.03% | 22.62B | |
| +20.22% | 19.55B | |
| +0.04% | 14.61B |
- Stock Market
- Equities
- COP Stock
- COP Stock
- Financials CompuGroup Medical Societas Europaea
